Overview

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery. Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor. Funding Source - FDA Office of Orphan Drug Products (OOPD)
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Angiotensin I (1-7)